Showing 41 - 60 results of 65,454 for search '(( 5 a decrease ) OR ((( 50 ((nn decrease) OR (mean decrease)) ) OR ( 5 ht decrease ))))', query time: 0.83s Refine Results
  1. 41
  2. 42

    Additional Analysis of visually induced calcium transients in Fig 6. by Maureen M. Sampson (9322886)

    Published 2020
    “…<p>Visually induced calcium transients were recorded in 5-HT2B +/- or 5-HT2B -/- flies as described in <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1009003#pgen.1009003.g006" target="_blank">Fig 6</a>. …”
  3. 43
  4. 44

    Serotonin modulates L2 neuron visually induced calcium transient kinetics. by Maureen M. Sampson (9322886)

    Published 2020
    “…Light or dark stimuli (A, middle panel, white and black vertical bars respectively) were flashed at random every 5 s for 6 min. …”
  5. 45

    Structure-Based Design of a Chemical Probe Set for the 5‑HT<sub>5A</sub> Serotonin Receptor by Anat Levit Kaplan (12126567)

    Published 2022
    “…Docking over 6 million molecules against a 5-HT<sub>5A</sub>R homology model identified 5 mid-μM ligands, one of which was optimized to <b>UCSF678</b>, a 42 nM arrestin-biased partial agonist at the 5-HT<sub>5A</sub>R with a more restricted off-target profile and decreased assay liabilities versus SB-699551. …”
  6. 46

    Structure-Based Design of a Chemical Probe Set for the 5‑HT<sub>5A</sub> Serotonin Receptor by Anat Levit Kaplan (12126567)

    Published 2022
    “…Docking over 6 million molecules against a 5-HT<sub>5A</sub>R homology model identified 5 mid-μM ligands, one of which was optimized to <b>UCSF678</b>, a 42 nM arrestin-biased partial agonist at the 5-HT<sub>5A</sub>R with a more restricted off-target profile and decreased assay liabilities versus SB-699551. …”
  7. 47

    RhoA gene expression and activity are impacted with increased intracellular 5HT. by Celeste M. Sheftel (9557588)

    Published 2020
    “…<p><b>A.</b><i>RhoA</i> mRNA expression is significantly upregulated with FLX and 5HTP compared to controls and is significantly decreased in FLX + MDC. …”
  8. 48

    Design, Synthesis, and Biological Evaluation of New Peripheral 5HT<sub>2A</sub> Antagonists for Nonalcoholic Fatty Liver Disease by Minhee Kim (1592440)

    Published 2020
    “…Here, structural modifications of pimavanserin (CNS drug), a 5HT<sub>2A</sub> antagonist approved for Parkinson’s disease, led us to synthesize new peripherally acting 5HT<sub>2A</sub> antagonists. …”
  9. 49
  10. 50
  11. 51
  12. 52
  13. 53
  14. 54
  15. 55
  16. 56
  17. 57

    Fig 5 - by Duyan Geng (12072181)

    Published 2022
    Subjects:
  18. 58
  19. 59
  20. 60